Analyst expected NDA acceptance- but believes the FDA news importantly lowers regulatory risk for ARRY.
Forecasting a potential $500 million yearly sales opportunity ahead, the analyst lifts price target on Array.
Commercial Revenues Are Likely in 2018 Despite Modest Delay in Filing
In a research report published Friday, Cantor analyst Mara Goldstein reiterated an Overweight rating on shares of Array Biopharma Inc (NASDAQ:ARRY) with a …
Alcobra Ltd (NASDAQ:ADHD) disappointed investors today with the news that its MEASURE trial failed to meet its primary endpoint based on investigator assessment …
Cantor analyst Mara Goldstein came out today with a bullish note on shares of Celgene Corporation (NASDAQ:CELG), after the pharma giant pre-announced 2016 results …
Cantor analyst Mara Goldstein sheds light on Seattle Genetics, Inc. (NASDAQ:SGEN) after the bad news broke of a FDA partial hold placed on clinical …
Mara Goldstein of research firm Cantor came out today with a bullish call on shares of Cytokinetics, Inc. (NASDAQ:CYTK).
In a research report released Monday, Cantor analyst Mara Goldstein reiterated a Buy rating on shares of Celgene Corporation (NASDAQ:CELG) with a price …
Yesterday, Celgene Corporation (NASDAQ:CELG) shares were trading up 6% after posting a robust third-quarter EPS beat. Subsequently, Cantor analyst Mara Goldstein reiterates a …
